Abstract
Hyperlipidemia is considered one of the key factors for cardiovascular diseases. Based
on earlier work on a series of 5-al-kyl-4-aryl-3-mercapto-(4H)-1,2,4-triazoles, for further lead modification, a series of 4-(substituted)amino-5-substituted-3-mercapto-(4H)-1,2,4-triazoles was designed. Target compounds were synthesized by the well known
Hoggarth synthesis of substituted 1,2,4-triazoles. Synthesized compounds were screened
for lipid lowering activity using the “Poloxamer 407 induced hyperlipidemia in rats”
model at a dose of 100 mg/kg p. o. Compounds were found to alter serum lipid levels
significantly. Most of the compounds significantly reduced serum cholesterol and triglyceride
levels. Some of the compounds were found to reduce triglycerides and elevate high
density lipoprotein (HDL) levels more than the standard drug atorvastatin (CAS 134523-03-8).
Compounds with chloro substitution on aryl rings were found more active in reducing
serum lipid levels than other substitutions.
Key words
Antihyperlipidemic activity - Cholesterol - High-density lipoprotein - Poloxamer 407
- Triazoles - Triglycerides
